Viridian Therapeutics, Inc. Common Stock (VRDN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 252
- Market Cap
- $2.2B
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
SentiSense also tracks daily options readings for Viridian Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Viridian Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.